



SOLUTION OVERVIEW

Structuring Global Biotech Expansion

Minimizing risk, maximizing value

As biotech companies aim to scale their supply chains internationally, strategic planning is key – not just for operational success, but for protecting shareholder value and minimizing risk exposure. DLA Piper offers bespoke guidance across employment law, IP strategy, legal entity structuring, tax, trade, credits and incentives and corporate governance to help you navigate this complex landscape.

How we help

Guiding you to global readiness

Expanding globally without a well-defined strategy can expose your company to foreign regulatory risk, increased regulatory oversight, complex disclosure requirements, lost opportunities for local incentives and unintended tax liabilities. Our integrated team guides you through each stage toward global readiness with strategic, practical advice.

A holistic approach

Our strategic approach positions you for successful joint ventures, acquisitions, and sustainable growth, so you can pursue global opportunities with confidence while protecting enterprise value.

Mitigating risk at every step

We mitigate risk through a staged framework that safeguards core US operations while enabling international growth, helping you stay compliant, protected, and well positioned for long-term success.

Avoiding regulatory pitfalls

Our experienced team helps you proactively address these risks, protect value, and make informed decisions as you scale.

Global tax strategy

Without careful planning, biotech companies expanding internationally could face foreign tax exposures and disclosure obligations, as well unintended US tax consequences, that could impact valuation. Timing is critical – setting up tax-efficient supply chains from the outset could prevent costly restructurings. We help you evaluate and implement tax-efficient structures and operating model to reduce your global tax burden, enhance earnings per share (EPS), and strengthen valuation.



Leading Firm

Life Sciences

*The Legal 500 US 2026 and
Chambers USA 2026*

Leading Firm

Life Sciences & Pharmaceutical Sector
(International and Cross-Border)

Chambers Global 2026

Leading Firm

Corporate/M&A

*Chambers Global:
Multi-Jurisdictional 2026*

Leading Firm

Employment

*Chambers Global:
Multi-Jurisdictional 2026*

Top Ranked

International Tax

The Legal 500 US 2026

Top Ranked

Tax

*Chambers Global:
Multi-Jurisdictional 2026*

A tailored framework for your success

Early structuring helps establish a foundation for strong international growth. Without prior planning, companies may face unnecessary financial costs, operational inefficiencies, legal and regulatory challenges, unintended tax and trade liabilities, and valuation-impacting disclosures.

Through our four-step framework, we help you:

1. **Assess** your growth plans, operating model, and revenue projections.
2. **Design** an efficient operating model, legal entity structure, IP ownership, and governance structure.
3. **Implement** your strategy across jurisdictions and business functions.
4. **Refine** your approach as your business, operations, and tax profile evolve.

Structuring before international revenue takes off

Acting early – ideally during late-stage clinical trials, before significant non-US revenue begins – could help maximize tax efficiency, safeguard core US operations, and support scalable global expansion.

Connect with us

With a portfolio of services to match every stage of the business lifecycle, we combine sector area knowledge with leading industry insights to help you shape your business and meet your toughest challenges.

Bespoke structuring across key domains

Every biotech company's expansion journey is different. As you prepare for global growth, considerations across employment, tax, trade, corporate, regulatory, and compliance often differ significantly between US and international markets. At DLA Piper, we help you build a tailored structure that coordinates these interconnected areas and aligns with your business objectives.

Employment

- **Key considerations:** Where key personnel will sit, how the workforce will be engaged, and how equity, benefits, immigration, and workforce compliance will be managed across jurisdictions.
- **Cross-border differences:** Local employment protections, employee classification rules, restrictive covenant standards, and benefits obligations may vary, while works councils and unions may introduce additional compliance requirements.
- **How we help:** We help you coordinate employment, immigration, tax, and corporate considerations across markets, so workforce decisions support your broader expansion strategy in a practical and scalable way.

Tax

- **Key considerations:** Tax planning, including legal entity structure, intellectual property ownership, transfer pricing, supply chain design, intercompany arrangements, withholding taxes, and future non-US revenue streams.
- **Cross-border differences:** Local incentives, treaty access, and evolving international tax rules may influence the optimal structure.
- **How we help:** By bringing together US and international tax teams, we help you design integrated structures that protect core US operations while supporting efficient global growth.

Corporate

- **Key considerations:** The right legal entity structure, governance model, intercompany arrangements, financing flexibility, board oversight, and readiness for future collaborations, licensing transactions, M&A, or exits.
- **Cross-border differences:** Director duties, capitalization rules, local filing obligations, foreign investment requirements, and approval processes may vary by jurisdiction.
- **How we help:** With one integrated team, we help you build and manage cross-border corporate structures, allowing legal entities, governance, and transaction planning to evolve alongside your commercial strategy.

Regulatory

- **Key considerations:** Applicable regulatory requirements and regulatory strategy, including preclinical testing, clinical trial design and oversight, product classification, market authorization pathways, labeling, manufacturing and quality systems, advertising and promotion, pharmacovigilance, post-market obligations, and communications with regulators.
- **Cross-border differences:** Local approvals, inspections, data requirements, labeling and warning standards, or market access rules may create different obligations, timelines, and risk profiles.
- **How we help:** Combining global reach with local insight to coordinate US and international regulatory advice, we help you align development, manufacturing, and commercialization activities with local requirements while minimizing cross-border complexity.

Compliance/Privacy

- **Key considerations:** Anti-corruption, HCP engagement, promotional practices, clinical trial compliance, data privacy, cybersecurity, cross-border data transfers, and the use of patient, genetic, or health-related data.
- **Cross-border differences:** GDPR-style obligations, local health data restrictions, enforcement priorities, and country-specific rules governing interactions with healthcare professionals and government stakeholders may vary significantly.
- **How we help:** We help you develop right-sized global compliance and privacy frameworks that are aligned across markets, practical for your business, and responsive to evolving regulatory expectations.

For more information

To learn more about DLA Piper, visit dlapiper.com or contact:



Emilio Ragosa

Partner
Global Co-Chair, Life Sciences and Healthcare
Short Hills, NJ
emilio.ragosa@us.dlapiper.com



Ciara McLoughlin

Partner
Employment
Dublin
ciara.mcloughlin@dlapiper.com




Marco de Morpurgo

Partner
Global Co-Chair, Life Sciences and Healthcare
Rome
marco.demorpurgo@dlapiper.com



Christopher Mikson

Partner
Regulatory
Philadelphia
christopher.mikson@us.dlapiper.com



Steven Davis

Partner
Tax
New York
steven.davis@us.dlapiper.com



Victoria Rhodes

Partner
Corporate
London
victoria.rhodes@dlapiper.com



Maura Dineen

Partner
Tax
Dublin
maura.dineen@dlapiper.com



Jeffrey Scott

Of Counsel
Compliance
Philadelphia
jeffrey.scott@us.dlapiper.com



Ute Krudewagen

Partner
Employment
Palo Alto
ute.krudewagen@us.dlapiper.com

dlapiper.com